louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02260336: The Effect of Panax Notoginseng Powders on Rheumatic Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rheumatic Pain
Lead sponsor: Chengdu PLA General Hospital
Sponsor class: OTHER
First posted: 2014-10-09
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of Panax Notoginseng Powders on Rheumatic Pain.


Eligibility criteria: Inclusion Criteria:

* had a diagnosis of classic or definite RA
* without conflict to the written, informed consent signed prior to the enrollment.

Exclusion Criteria:

* uncontrolled medical problems
* organic brain syndrome
* major psychiatric disturbances
* major communicative disorders
* a history of severe noncompliance
* less than 7 years of formal education, or illiteracy
* being included in other clinical trial within the last 4 weeks
* with abnormal liver or kidney function (more than 1 time above the high normal)
* with serious cardiovascular disease
* with hematologic disease
* being in pregnancy, lactation period or under a pregnancy plan
* with severe gastrointestinal disease
* with contraindication or being allergic to the test drugs
* being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs
* being not compatible for the trial medication, or other circumstances at the discretion of investigators
* without legal capacity or only with limited legal capacity

Primary outcomes:
measure: Change from Baseline in McGill Pain Questionnaire (MPQ) score at 24 weeks
timeFrame: at 0 week, 6 weeks, 12 weeks, 24 weeks
measure: Change from Baseline in Visual Analog Scale(VAS) score at 24 weeks
timeFrame: at 0 week, 6 weeks, 12 weeks, 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu city
country: China
facility: 270 Rongdu street, Jin-niu district,Rheumatology Center of Integrated Medicine, General Hospital of Chengdu Military Area Command PLA，
state: Sichuan
Study officials:
References:
Clinical trial NCT02108236: Effectiveness and Safety of Acupuncture for Obesity and Over-weight People
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Obesity
Overweight
Keywords: acupuncture
chinese traditional medicine
Lead sponsor: Heilongjiang University of Chinese Medicine
Sponsor class: OTHER
First posted: 2014-04-09
Enrollment: 110
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the efficacy and safety of acupuncture for obesity and overweight people in China.


Eligibility criteria: Inclusion Criteria:

* The individuals is phlegm-dampness constitution and female.
* Age is between 18 and 45 years.
* BMI is between 24 and 50.
* The individuals voluntarily sign the informed consent form.
* The individuals live in Harbin City of China.

Exclusion Criteria:

* Secondary obesity, eg:pituitary diseases, hypothalamic disorder, hypothyroidism, pancreatic diseases，hyperadrenocorticism, postmenopausal obesity etc.
* The individuals with server cardiovascular and cerebrovascular diseases and cancer.
* Having therapy for obesity in the last three months.
* The individuals do not adhere to the treatment or are with other treatments.
* Female individuals with pregnancy, lactation and planning a pregnancy in the two months.
* Critical patients or patients combined with liver and kidney damage.
* Individuals with visual and auditory memory disorders or psychosis.

Primary outcomes:
measure: body mass index(BMI)
timeFrame: 2 month after treatment
Secondary outcomes:
measure: waist-to-hip ratio (WHR)
timeFrame: 2 month after treatment
measure: Blood sugar
timeFrame: 2 month after treatment
measure: Total cholesterol
timeFrame: 2 month after treatment
measure: Triglycerides
timeFrame: 2 month after treatment
measure: High-density lipoprotein cholesterol
timeFrame: 2 month after treatment
measure: Low-density lipoprotein cholesterol
timeFrame: 2 month after treatment
Other outcomes:
Locations:
city: Harbin
country: China
facility: The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
state: Heilongjiang
Study officials:
affiliation: First Affiliated Hospital of Heilongjiang Chinese Medicine University
name: Sun Zhongren
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06465836: Simplified Conservative Measures in Managing Morbidly Adherent Placenta in Beni-Suef University
Official title: Beni-Suef University Hospital Simplified Conservative Approach for Managing Placenta Accreta Spectrum: RCT
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Placenta Accreta
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2024-06-20
Enrollment: 172
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients will be randomized into two groups. One of two intraoperative surgical interventions that will be evolved during the study period:

Group A: In which 86 patients will have bilateral uterine artery ligations as described by the O- lreay technique in addition to standard conservative methods. The stitches were tied securely anteriorly.

Group B: which will include 86 patients we will do our simplified approach which include;

* After placental separation; try to grasp lower segment, or cervical flap.
* Close uterine cavity by continuous vicryl no 1 suture.
* Do 3 to 4 mattress sutures as the second layer of the uterus.
* Do uterine ligation with compression of the lower uterine segment (Modification of O, lreay suture).
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy of modified uterine artery ligation and myometrial compression as a conservative measure in improving the prognosis of the morbidly adherent placenta.

Detailed description: According to the International Federation of Gynecology and Obstetrics (FIGO) guidelines, the principal surgical strategy to prevent excessive bleeding related to placenta accreta syndrome is to leave the placenta in situ and perform a primary peripartum hysterectomy at delivery. A hysterectomy may not be preferred by patients wishing to preserve fertility and is detrimental to multiple aspects of the pelvic floor, bowel, and physical functions.

Surgical principles in placenta accreta syndrome include avoiding disruption of the hypervascular placenta, stepwise devascularization, early and comprehensive blood product transfusion, and judicious use of interventional radiologic techniques such as vascular embolization.

Conservative management describes any approach whereby hysterectomy is avoided

Eligibility criteria: Inclusion Criteria:

* Gestational age more than 28 weeks as determined by LMP and ultrasound.
* Placenta previa as confirmed by ultrasound.
* Clinically stable with no or mild vaginal bleeding.
* No evidence of fetal compromise.
* Patient consent.

Exclusion Criteria:

* Vaginal bleeding
* Medical disorders

Primary outcomes:
measure: Amount of blood loss
timeFrame: 6 hours postoperatively
Secondary outcomes:
measure: Maternal morbidity
timeFrame: 24 hours post operatively
measure: Maternal mortality
timeFrame: 24 hours postoperatively
Other outcomes:
measure: Gynecological conditions
timeFrame: 6 months
Locations:
city: Cairo
country: Egypt
facility: Beni-Suef University
Study officials:
References:
Clinical trial NCT00769236: Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease
Official title: Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Crohn's Disease
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2008-10-09
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: We propose to study the intestinal secretion of ASCA by evaluating them in biopsy culture supernatants from a cohort of patients suffering from CD (n=80) and a cohort of control patients (UC (n=40) and patients without IBD (n=40 )).

Detailed description: Its diagnosis is based upon clinical, endoscopic and histological parameters but recent studies have shown that seric evaluation of immunological markers (anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic auti-antibodies (ANCA)) could be useful. Crohn's disease (CD) is an inflammatory bowel disease (IBD) of the young people. Antibodies anti-chitobisoside carbohydrate (ACCA), anti-laminaribioside carbohydrate (ALCA) and anti-mannobioside carbohydrate (AMCA) have been described as new serological markers of CD.

Eligibility criteria: Inclusion Criteria:

* Patients reached by disease of crohn
* patients reached by hemorrhagic first side-colitis

Exclusion Criteria:

* Forms ileales or ano-périneales pure of disease of crohn
* indefinite colitis

Primary outcomes:
measure: Compare the performances of the dosage of the ASCA in floating it of culture of intestinal biopsies in that of their dosage in the serum
timeFrame: 24 months
Secondary outcomes:
measure: Determine if the patients reached by disease of crohn not presenting ASCA in their serum represent one under group of disease of crohn
timeFrame: 24 months
Other outcomes:
Locations:
city: Marseille
country: France
facility: Laboratoire d'Immunologie - Hopital de la Conception
Study officials:
affiliation: Assistance Publique des Hopitaux de Marseille
name: Sophie Desplat-Jego, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05939336: MOS Prebiotic Potential in Older Adults
Official title: The Prebiotic Potential of a Yeast Cell Wall Fraction Containing Mannooligosaccharides and β-glucans.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Healthy
Keywords: Healthy
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: Lallemand Bio-Ingredients
First posted: 2023-07-11
Enrollment: 40
Sex: ALL
Minimum age (years): 50
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Detailed description: Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Eligibility criteria: Inclusion Criteria:

* Adults 50-99 years of age.
* Able to provide written informed consent in English.
* Willingness to complete all study procedures
* Healthy or diagnoses with Parkinson's or multiple system atrophy

Exclusion Criteria:

* Yeast allergy.
* Self-reported kidney disease.
* Elite athletes or long-distance runners.
* Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
* Current use of laxatives or antidiarrheal medications.
* Use of other investigational products within 3 months of the screening visit.
* Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
* Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
* Current cancer treatment
* Currently pregnant

Primary outcomes:
measure: Mean daily rating of gastrointestinal symptoms
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Food Science and Human Nutrition Department, University of Florida
state: Florida
Study officials:
References:
Clinical trial NCT02283736: Efficacy of Oral Probiotic Administration in Patients With Chronic Periodontitis
Official title: Efficacy of Oral Probiotic Administration in Clinical, Immunological and Microbiological Parameters of Patients With Chronic Periodontitis Treated With Non Surgical Periodontal Treatment.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: -Chronic Periodontitis
Keywords: Chronic periodontitis
Probiotics
Non- surgical treatment
Lead sponsor: University of Chile
Sponsor class: OTHER
First posted: 2014-11-05
Enrollment: 36
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized placebo- controlled clinical trial is to evaluate the effects of Lactobacillus rhamnosus SP1- containing probiotic tablets as an adjunct to scaling and root planning (SRP).

Material and methods: Thirty six chronic periodontitis patients will be recruited and monitored clinically, immunologically and microbiologically at baseline, 3 and 6 months after therapy. All patients will receive scaling and root planning and randomly will be assigned over an experimental (SRP + probiotic, n=18) or control (SRP + placebo, n=18) group. The tablets will be used once per day during 3 months.


Eligibility criteria: Inclusion Criteria:

* ≥14 natural teeth, excluding third molars
* ≥10 posterior teeth
* ≥35 years old
* ≥ 5 teeth with periodontal sites with probing depths ≥5mm, clinical attachment loss ≥3mm
* Bleeding on probing ≥20% of sites
* Extensive bone loss determined radiographically

Exclusion Criteria:

* Periodontal treatment before the time of examination
* Systemic illness
* Pregnancy
* Anticoagulant, antibiotics and non- steroid anti- inflammatory therapy in the 6-month period before the study

Primary outcomes:
measure: Differences of at least 1mm between groups for clinical attachment level changes
timeFrame: baseline, 3, 6 months
Secondary outcomes:
measure: Differences between groups for probing depth changes
timeFrame: baseline, 3, 6 month
measure: Differences between groups for bleeding on probing changes
timeFrame: baseline, 3, 6 months
measure: Differences between groups for plaque index changes
timeFrame: baseline, 3, 6 months
measure: Differences between groups for levels of Interleukin (IL)-17, IL-21, Transforming Growth Factor (TGF)- beta, IL-10, RANKL changes in gingival crevicular fluid
timeFrame: baseline, 3, 6 months
measure: Differences between groups for levels of periodontal pathogens changes
timeFrame: baseline, 3, 6 months
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Faculty of Dentistry of University of Chile
Study officials:
affiliation: Faculty of Dentistry of University of Chile
name: Jorge Gamonal, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03062436: To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission
Official title: Stopping Imatinib Therapy in CML Patients With Sustained Molecular Remission
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Myeloid Leukemia
Treatment Free Remission
Keywords: CML, treatment free remission
Lead sponsor: Command Hospital, India
Sponsor class: OTHER_GOV
First posted: 2017-02-23
Enrollment: 27
Sex: ALL
Minimum age (years): 12
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with chronic myeloid leukemia (CML) are conventionally put on life long therapy with tyrosine kinase inhibitor drugs (Imatinib mesylate in India). Patients who achieve a deep molecular response which has been sustained for at least three years, can be taken off the drug therapy. Thereafter a close monitoring is required to monitor their disease relapse. In case there is evidence of disease recurrence on highly sensitive molecular assays, their drug therapy is restarted. The study aims to identify proportion of patients who can be kept off drug therapy in a state of sustained molecular remission.

Detailed description: While a large number of studies which have stopped TKI therapy in similar patients exist in Europe and USA, no such study has been done on Indian or other south Asian population. Almost all studies done previously have noted that in relapsed patients, who show disease recurrence on stopping their TKI therapy, their remission state is regained once the TKI therapy is restarted.

Eligibility criteria: Inclusion Criteria:

1. Patients of CML on TKI (Imatinib) therapy for more than 5 years
2. Patients who have been in complete molecular response (MR 4.5 +) for at least three years

Exclusion Criteria:

1. Patients who ever had blast crisis
2. Patients achieving molecular response with second generation TKI due to failure of Imatinib

Primary outcomes:
measure: Disease Recurrence
timeFrame: 12 months from cessation of the drug therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Pune
country: India
facility: Command Hospital
state: Maharashtra
Study officials:
References:
Clinical trial NCT01057836: Effect of Neck Strength Training on Health-related Quality of Life in Females With Neck Pain
Official title: Effect of Neck Strength Training on Health-related Quality of Life in Females With Chronic Neck Pain: A Randomized Controlled 1-year Follow-up Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Lead sponsor: Jyväskylä Central Hospital
Sponsor class: OTHER
First posted: 2010-01-27
Enrollment: 180
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 53
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether intensive one-year neck strength training can enhance health related quality of life in females with chronic neck pain.


Eligibility criteria: Inclusion Criteria:

* female
* aged 25 to 53 years
* office worker
* permanently employed
* motivated to continue working
* motivated for rehabilitation
* constant or frequently occurring neck pain for more than 6 months

Exclusion Criteria:

* severe disorders of the cervical spine
* disk prolapse
* spinal stenosis
* postoperative conditions in the neck and shoulder areas
* history of severe trauma
* instability
* spasmodic torticollis
* frequent migraine
* peripheral nerve entrapment
* fibromyalgia
* shoulder diseases (tendonitis, bursitis, capsulitis)
* inflammatory rheumatic diseases
* severe psychiatric illness and other diseases that prevent physical loading
* pregnancy

Primary outcomes:
measure: 15 Dimensional instrument
Secondary outcomes:
Other outcomes:
Locations:
city: Punkaharju
country: Finland
facility: Punkaharju Rehabilitation Centre
Study officials:
affiliation: Central Finland Health Care District
name: Jari Ylinen, PhD, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Salo PK, Hakkinen AH, Kautiainen H, Ylinen JJ. Effect of neck strength training on health-related quality of life in females with chronic neck pain: a randomized controlled 1-year follow-up study. Health Qual Life Outcomes. 2010 May 14;8:48. doi: 10.1186/1477-7525-8-48.
Clinical trial NCT01501019: Exercise in Sjogren, Myositis and Takayasu's Arteritis
Official title: Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Primary Sjogren´s Syndrome
Myositis
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2011-12-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Exercise may improve physical capacity and health parameters in Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.

Therefore, this study aims to investigate the role of an exercise training program in patients with Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.


Eligibility criteria: Inclusion Criteria:

* Physically inactive
* Stable drugs regime for at least three months

Exclusion Criteria:

* Other rheumatic diseases
* Physical disability that prevent the patient to perform the physical tests
* Severe pulmonary disease

Primary outcomes:
measure: Aerobic Capacity
timeFrame: Twelve weeks
measure: Muscle strength
timeFrame: Twelve weeks
measure: Quality of life
timeFrame: Twelve weeks
Secondary outcomes:
measure: Serum anti-inflammatory cytokines
timeFrame: Twelve weeks
measure: Serum pro-inflammatory cytokines
timeFrame: Twelve weeks
measure: Serum inflammatory markers
timeFrame: Twelve weeks
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: University of Sao Paulo School of Medicine Clinical Hospital
Study officials:
References:
citation: Mattar MA, Gualano B, Perandini LA, Shinjo SK, Lima FR, Sa-Pinto AL, Roschel H. Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis. Arthritis Res Ther. 2014 Oct 25;16(5):473. doi: 10.1186/s13075-014-0473-5.